A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Latest Information Update: 30 Nov 2023
At a glance
- Drugs Onvansertib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Cardiff Oncology
- 28 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2023 According to a Cardiff Oncology media release, the company will host a corresponding conference call and live webcast at 5:00 p.m. ET/2:00 p.m. PT on September 26, 2023 to discuss the results of this study.
- 26 Sep 2023 Results presented in a Cardiff Oncology media release.